Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight

Journal of Pediatrics

Volumn 147, Issue 2, 2005, Pages 172-179

  Kaufman, David ^a   Boyle, Robert ^b   Hazen, Kevin C ^b   Patrie, James T ^b   Robinson, Melinda ^b   Grossman, Leigh B ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PLACEBO;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ARTICLE; BIRTH WEIGHT; CANDIDIASIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENDOTRACHEAL TUBE; FEMALE; FUNGUS ISOLATION; HEALTH CARE COST; HEALTH SURVEY; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEPSIS;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CATHETERIZATION, CENTRAL VENOUS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUCONAZOLE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INTENSIVE CARE UNITS, NEONATAL; INTUBATION, INTRATRACHEAL; MALE; MICROBIAL SENSITIVITY TESTS; RISK FACTORS;

EID: 23944516822     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2005.03.036     Document Type: Article

References (29)

1. D. Kaufman, R. Boyle, K.C. Hazen, J.T. Patrie, M. Robinson, and L.G. Donowitz Fluconazole prophylaxis against fungal colonization and infection in preterm infants N Engl J Med 345 2001 1660 1666
2. T.C. White Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus Antimicrob Agents Chemother 41 1997 1482 1487
3. T.C. White The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans Antimicrob Agents Chemother 41 1997 1488 1494
4. T.C. White, M.A. Pfaller, M.G. Rinaldi, J. Smith, and S.W. Redding Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient Oral Dis 3 suppl 1 1997 S102 S109
5. L. Million, A. Manteaux, G. Reboux, C. Drobacheff, M. Monod, and T. Barale Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype J Clin Microbiol 32 1994 1115 1118
6. M.M. Balkis, S.D. Leidich, P.K. Mukherjee, and M.A. Ghannoum Mechanisms of fungal resistance: an overview Drugs 62 2002 1025 1040
7. T.C. White, K.A. Marr, and R.A. Bowden Clinical, cellular, and molecular factors that contribute to antifungal drug resistance Clin Microbiol Rev 11 1998 382 402
8. H. Saxen, K. Hoppu, and M. Pohjavuori Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life Clin Pharmacol Ther 54 1993 269 277
9. K.W. Brammer, and P.E. Coates Pharmacokinetics of fluconazole in pediatric patients Eur J Clin Microbiol Infect Dis 13 1994 325 329
10. J.D. Sobel, H.C. Wiesenfeld, M. Martens, P. Danna, T.M. Hooton, and A. Rompalo Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis N Engl J Med 351 2004 876 883
11. W.T. Hughes, G.K. Rivera, M.J. Schell, D. Thornton, and L. Lott Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis N Engl J Med 316 1987 1627 1632
12. E.T. Houang, O. Chappatte, D. Byrne, P.V. Macrae, and J.E. Thorpe Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis Antimicrob Agents Chemother 34 1990 909 910
13. S.L. Vaden, M.C. Heit, E.C. Hawkins, C. Manaugh, and J.E. Riviere Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid J Vet Pharmacol Ther 20 1997 181 186
14. P. Schuman, L. Capps, G. Peng, J. Vazquez, W. el Sadr, and A.I. Goldman Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: a randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS Ann Intern Med 126 1997 689 696
15. H. Saxen, M. Virtanen, P. Carlson, K. Hoppu, M. Pohjavuori, and M. Vaara Neonatal Candida parapsilosis outbreak with a high case fatality rate Pediatr Infect Dis J 14 1995 776 781
16. A.A. Fanaroff, S.B. Korones, L.L. Wright, J. Verter, R.L. Poland, and C.R. Bauer Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network Pediatr Infect Dis J 17 1998 593 598
17. A.D. Spicer, and K.C. Hazen Rapid confirmation of Candida Albicans identification by combination of two presumptive tests Med Microbiol 1 1992 284 289 Letter
18. K.C. Hazen, E.J. Baron, A.L. Colombo, C. Girmenia, A. Sanchez-Sousa, and A. del Palacio Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion J Clin Microbiol 41 2003 5623 5632
19. K.C. Hazen, and S.A. Howell Candida, Cryptococcus and other yeasts of importance P.R. Murray E.J. Baron J.H. Jorgensen M.A. Pfaller R.H. Yolken Manual of Clinical Microbiology 8th ed. 2003 ASM Press Washington, D.C. 1693 1711
20. National Committee of Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeats; approved standard. NCCLS document M27-A ed. 1997.
21. A. Agresti, and Y. Min On small-sample confidence intervals for parameters in discrete distributions Biometrics 57 2001 963 971
22. B.A. Yoder, D.A. Sutton, V. Winter, and J.J. Coalson Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model Pediatr Infect Dis J 23 2004 687 688
23. B.J. Stoll, N. Hansen, A.A. Fanaroff, L.L. Wright, W.A. Carlo, and R.A. Ehrenkranz Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network Pediatrics 110 2 pt 1 2002 285 291
24. E.H. Kossoff, E.S. Buescher, and M.G. Karlowicz Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases Pediatr Infect Dis J 17 1998 504 508
25. D.K. Benjamin Jr., E.R. DeLong, W.J. Steinbach, C.M. Cotton, T.J. Walsh, and R.H. Clark Empirical therapy for neonatal candidemia in very low birth weight infants Pediatrics 112 3 pt 1 2003 543 547
26. L. Saiman, E. Ludington, M. Pfaller, S. Rangel-Frausto, R.T. Wiblin, and J. Dawson Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group Pediatr Infect Dis J 19 2000 319 324
27. I.R. Makhoul, P. Sujov, T. Smolkin, A. Lusky, and B. Reichman Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey Pediatrics 109 2002 34 39
28. S.D. Kicklighter, S.C. Springer, T. Cox, T.C. Hulsey, and R.B. Turner Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant Pediatrics 107 2001 293 298
29. W. McGuire, L. Clerihew, and N. Austin Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants The Cochrane Database of Systemic reviews 2004 1 CD003850